Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomas

Virus Research

Volumn 127, Issue 1, 2007, Pages 43-48

  Govan, V A ^a   Williamson, A L ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

CRPV; rBCG; Therapeutic vaccine

Indexed keywords

BCG VACCINE; PROTEIN COTTONTAIL RABBIT PAPILLOMAVIRUS L2E7E2; PROTEIN E7; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CANCER INHIBITION; CONTROLLED STUDY; COTTONTAIL RABBIT PAPILLOMAVIRUS; IMMUNIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMA; PRIORITY JOURNAL; RABBIT; TUMOR REGRESSION;

ANIMALS; ANTIGENS, VIRAL; BCG VACCINE; COTTONTAIL RABBIT PAPILLOMAVIRUS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; RABBITS; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

COTTONTAIL RABBIT PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS; ORYCTOLAGUS CUNICULUS; PAPILLOMAVIRIDAE;

EID: 34249086035     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.03.016     Document Type: Article

References (28)

1. Bastien N., and McBride A.A. Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology 270 (2000) 124-134
2. Brandsma, J.L., Shlyankevich, M., Buonocore, L., Roberts, A., Becker, S.M., Rose, J.K., 2006. Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine. August 22 (Epub ahead of print).
3. Brandsma J.L., Shlyankevich M., Zhang L., Slade M.D., Goodwin E.C., Peh W., and Deisseroth A.B. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J. Virol. 78 (2004) 116-123
4. de Jong A., O'Neill T., Khan A.Y., Kwappenberg K.M., Chisholm S.E., Whittle N.R., Dobson J.A., Jack L.C., St Clair Roberts J.A., Offringa R., van der Burg S.H., and Hickling J.K. Enhancement of human papillomavirus (HPV) type 16 E6- and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20 (2002) 3456-3464
5. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Exp. Opin. Biol. Ther. 4 (2004) 1-14
6. Ferlay J., Bray B., Pisani P., and Parkin D.M. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARC Press, Lyon
7. Fiander A.N., Tristram A.J., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., Sterling J.C., and Kitchener H.C. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int. J. Gynecol. Cancer 16 (2006) 1075-1081
8. Frazer I. Prevention of cervical cancer through papillomavirus vaccination. Nature Rev. Immunol. 4 (2004) 46-54
9. Galloway D.A. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis. 3 (2003) 469-475
10. Gheorghiu M., Lagranderie M.R., Gicquel B.M., and Leclerc C.D. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun. 62 (1994) 4287-4295
11. Govan V.A. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the e6 and e7 oncogenes. Ann. NY Acad. Sci. 1056 (2005) 328-343
12. Govan V.A., Christensen N.D., Berkower C., Jacobs Jr. W.R., and Williamson A.L. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24 (2006) 2087-2093
13. Han R., Reed C.A., Cladel N.M., and Christensen N.D. Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine 17 (1999) 1558-1566
14. Jabbar I.A., Fernando G.J., Saunders N., Aldovini A., Young R., Malcolm K., and Frazer I.H. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18 (2000) 2444-2453
15. Kameoka M., Nishino Y., Matsuo K., Ohara N., Kimura T., Yamazaki A., Yamada T., and Ikuta K. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12 (1994) 153-158
16. Kawahara M., Matsuo K., Nakasone T., Hiroi T., Kiyono H., Matsumoto S., Yamada T., Yamamoto N., and Honda M. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 21 (2002) 158-166
17. Koutsky L.A., and Harper D.M. Current findings from prophylactic HPV vaccine trials. Vaccine Suppl. 3 (2006) S114-S121 (Chapter 13)
18. Lacey C.J., Lowndes C.M., and Shah K.V. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 (2006) 35-41 (Chapter 4)
19. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24S3 (2006) S1-S10 (Chapter 1)
20. Palmer K.E., Benko A., Doucette S.A., Cameron T.I., Foster T., Hanley K.M., McCormick A.A., McCulloch M., Pogue G.P., Smith M.L., and Christensen N.D. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24 (2006) 5516-5525
21. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 3 (2006) S11-S25 (Chapter 2)
22. Roden R.B., Yutzy IV W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 (2000) 254-257
23. Schiller J.T., and Nardelli-Haefliger D. Second generation HPV vaccines to prevent cervical cancer. Vaccine 24 (2006) S147-S153 (Chapter 17)
24. Snapper S.B., Lugosi L., and Jekkel A. Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6987-6991
25. Stover C.K., De La Cruz V.F., Fuerst T.R., Hanson M.S., Fuerst T.R., Jacobs Jr. W.R., and Bloom B.R. New use of BCG for recombinant vaccines. Nature 351 (1991) 456-460
26. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., and Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 (2001) 3652-3660
27. World Health Organisation (WHO), 2004. Vaccines against human papillomavirus. Available at: http://www.who.int/vaccines/en/hpvrd.shtml/shtml (accessed July 12).
28. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350